伊马替尼和伊布司特对多发性硬化症大鼠模型可能改善作用的比较研究

IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Monica Gamal Fawzy, Mohsen Sami Selim, Omayma Anwar Khorshid, Laila Ahmed Rashed, Miran Atif Elkordy, Noha Samir Abdel Latif
{"title":"伊马替尼和伊布司特对多发性硬化症大鼠模型可能改善作用的比较研究","authors":"Monica Gamal Fawzy,&nbsp;Mohsen Sami Selim,&nbsp;Omayma Anwar Khorshid,&nbsp;Laila Ahmed Rashed,&nbsp;Miran Atif Elkordy,&nbsp;Noha Samir Abdel Latif","doi":"10.1186/s43094-025-00801-x","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>This is an experimental comparative study of the ameliorative effects of imatinib and ibudilast in multiple sclerosis induced in rats by cuprizone. Forty healthy adult male rats were used and divided into five groups: normal control, solvent control, multiple sclerosis model, imatinib- and ibudilast-treated groups. To detect behavioural changes, hang wire test was done for motor assessment, Morris water maze test was done to assess long-term memory, and Y-maze test was done to assess short-term memory. The tests were done on the last day of the experiment. At the end of the study, rats were sacrificed, and brains were extracted. From the brain samples, the right hemispheres were used for measurement of biochemical parameters from brain homogenates. While the left hemispheres were used for pathological and immunohistochemical examination.</p><h3>Results</h3><p>Treated groups showed improvement whereas ibudilast showed improvement in the behavioural tests, MAPK, IL-17, TNF-α and histopathological examination. While imatinib showed improvement in NFκB, MBP, SOD and nitric oxide.</p><h3>Conclusion</h3><p>Both imatinib and ibudilast had neuroprotective role in multiple sclerosis; however, ibudilast showed better results in improving neurological manifestations, biochemical and pathological parameters. This sets ibudilast as a promising drug to help slow down the pathogenesis of multiple sclerosis.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00801-x","citationCount":"0","resultStr":"{\"title\":\"Comparative study on the possible ameliorative effects of imatinib and ibudilast in a rat model of multiple sclerosis\",\"authors\":\"Monica Gamal Fawzy,&nbsp;Mohsen Sami Selim,&nbsp;Omayma Anwar Khorshid,&nbsp;Laila Ahmed Rashed,&nbsp;Miran Atif Elkordy,&nbsp;Noha Samir Abdel Latif\",\"doi\":\"10.1186/s43094-025-00801-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>This is an experimental comparative study of the ameliorative effects of imatinib and ibudilast in multiple sclerosis induced in rats by cuprizone. Forty healthy adult male rats were used and divided into five groups: normal control, solvent control, multiple sclerosis model, imatinib- and ibudilast-treated groups. To detect behavioural changes, hang wire test was done for motor assessment, Morris water maze test was done to assess long-term memory, and Y-maze test was done to assess short-term memory. The tests were done on the last day of the experiment. At the end of the study, rats were sacrificed, and brains were extracted. From the brain samples, the right hemispheres were used for measurement of biochemical parameters from brain homogenates. While the left hemispheres were used for pathological and immunohistochemical examination.</p><h3>Results</h3><p>Treated groups showed improvement whereas ibudilast showed improvement in the behavioural tests, MAPK, IL-17, TNF-α and histopathological examination. While imatinib showed improvement in NFκB, MBP, SOD and nitric oxide.</p><h3>Conclusion</h3><p>Both imatinib and ibudilast had neuroprotective role in multiple sclerosis; however, ibudilast showed better results in improving neurological manifestations, biochemical and pathological parameters. This sets ibudilast as a promising drug to help slow down the pathogenesis of multiple sclerosis.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00801-x\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-025-00801-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00801-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

本实验比较了伊马替尼和伊布司特对铜吡酮所致大鼠多发性硬化症的改善作用。选取健康成年雄性大鼠40只,分为正常对照组、溶剂对照组、多发性硬化症模型组、伊马替尼组和布替司特组。为检测行为变化,采用吊丝测验评估运动记忆,Morris水迷宫测验评估长期记忆,y形迷宫测验评估短期记忆。测试是在实验的最后一天进行的。在研究结束时,大鼠被处死,提取大脑。从大脑样本中,右半球被用来测量大脑匀浆的生化参数。左半球进行病理和免疫组化检查。结果治疗组在行为学测试、MAPK、IL-17、TNF-α及组织病理学检查中均有改善,而布司特组在行为学测试中均有改善。而伊马替尼对NFκB、MBP、SOD和一氧化氮均有改善作用。结论伊马替尼和伊布司特对多发性硬化症均有神经保护作用;然而,布司特在改善神经学表现、生化和病理指标方面表现出更好的效果。这使伊布司特成为一种有希望帮助减缓多发性硬化发病机制的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative study on the possible ameliorative effects of imatinib and ibudilast in a rat model of multiple sclerosis

Background

This is an experimental comparative study of the ameliorative effects of imatinib and ibudilast in multiple sclerosis induced in rats by cuprizone. Forty healthy adult male rats were used and divided into five groups: normal control, solvent control, multiple sclerosis model, imatinib- and ibudilast-treated groups. To detect behavioural changes, hang wire test was done for motor assessment, Morris water maze test was done to assess long-term memory, and Y-maze test was done to assess short-term memory. The tests were done on the last day of the experiment. At the end of the study, rats were sacrificed, and brains were extracted. From the brain samples, the right hemispheres were used for measurement of biochemical parameters from brain homogenates. While the left hemispheres were used for pathological and immunohistochemical examination.

Results

Treated groups showed improvement whereas ibudilast showed improvement in the behavioural tests, MAPK, IL-17, TNF-α and histopathological examination. While imatinib showed improvement in NFκB, MBP, SOD and nitric oxide.

Conclusion

Both imatinib and ibudilast had neuroprotective role in multiple sclerosis; however, ibudilast showed better results in improving neurological manifestations, biochemical and pathological parameters. This sets ibudilast as a promising drug to help slow down the pathogenesis of multiple sclerosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
44
审稿时长
23 weeks
期刊介绍: Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信